Provided by Tiger Trade Technology Pte. Ltd.

Vaxcyte, Inc.

62.03
-0.5900-0.94%
Volume:305.88K
Turnover:18.94M
Market Cap:9.23B
PE:-8.11
High:63.05
Open:62.30
Low:61.23
Close:62.62
52wk High:65.00
52wk Low:29.87
Shares:148.81M
Float Shares:136.00M
Volume Ratio:0.45
T/O Rate:0.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.6496
EPS(LYR):-5.6333
ROE:-36.51%
ROA:-22.61%
PB:3.35
PE(LYR):-11.01

Loading ...

Vaxcyte Is Maintained at Buy by BTIG

Dow Jones
·
Feb 26

Regulatory Timing Risks: How FDA Delays Could Derail Vaxcyte’s Development and Commercialization Plans

TIPRANKS
·
Feb 26

Vaxcyte: Buy Rated on Superior VAX-31 Coverage, Robust Phase 3 OPUS Program, and Strong Cash Runway Through 2028

TIPRANKS
·
Feb 26

Vaxcyte price target raised to $89 from $85 at BTIG

TIPRANKS
·
Feb 26

Jefferies Reaffirms Their Buy Rating on Vaxcyte (PCVX)

TIPRANKS
·
Feb 25

Vaxcyte price target lowered to $133 from $134 at BofA

TIPRANKS
·
Feb 25

Stock Track | Vaxcyte Soars 5.09% Intraday on Multiple Analyst Price Target Increases

Stock Track
·
Feb 25

Analysts Conflicted on These Healthcare Names: Catalyst Pharma (CPRX), Vaxcyte (PCVX) and Acadia Healthcare (ACHC)

TIPRANKS
·
Feb 25

Vaxcyte price target raised to $75 from $50 at TD Cowen

TIPRANKS
·
Feb 25

Vaxcyte Inc : TD Cowen Raises Target Price to $75 From $50

THOMSON REUTERS
·
Feb 25

BRIEF-Vaxcyte Enters Into Sales Agreement, May Sell Shares Of Common Stock Of Up To $500 Million

Reuters
·
Feb 25

Vaxcyte Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Feb 25

Vaxcyte Inc - Terminates Open Market Sale Agreement Dated as of July 1, 2021 - SEC Filing

THOMSON REUTERS
·
Feb 25

Vaxcyte Inc: Entered Into Sales Agreement, May Sell Shares of Common Stock of up to $500 Mln From Time to Time

THOMSON REUTERS
·
Feb 25

Vaxcyte reports Q4 EPS ($5.63) vs ($3.80) last year

TIPRANKS
·
Feb 25

Vaxcyte posts FY 2025 net loss of USD 766.6 million, up 65.2%

Reuters
·
Feb 25

Vaxcyte Q4 EPS $(1.80) Misses $(1.56) Estimate

Benzinga Earnings
·
Feb 25

Vaxcyte Inc: About $2.4 Bln in Cash, Cash Equivalents and Investments as of Dec 31, 2025

THOMSON REUTERS
·
Feb 25

Press Release: Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Feb 25

Vaxcyte’s VAX-31 Moves Into Phase 3: What This Pneumococcal Vaccine Update Means for PCVX Investors

TIPRANKS
·
Feb 21